Selective Late-Timepoint 68Ga-PSMA-11 PET/CT in Prostate Cancer: A Management-Focused Framework

68Ga-PSMA-11 PET/CT has the most established evidence base among PSMA-targeted imaging agents for prostate cancer and is incorporated into clinical guidelines internationally for initial staging, prostate-specific antigen (PSA) persistence, biochemical recurrence (BCR), and selection for PSMA-directed therapy. Its integration into routine clinical practice reflects established acquisition workflows and consistently high diagnostic performance, including localization of small-volume nodal and distant disease that may be occult on conventional imaging. Imaging is generally performed approximately 60 min after 68Ga-PSMA-11 administration; however, interest in additional image acquisition at a later timepoint (i.e., late-timepoint imaging) has emerged, with evidence from published studies and real-world experience from centers of excellence supporting feasibility and utility for select clinical scenarios. This additional late (generally 90 min to 3 h) acquisition may improve lesion-to-background contrast or help characterize low-level uptake, indeterminate findings, and suspected recurrence adjacent to physiologic urinary activity. However, improved contrast or lesion detection does not consistently translate into changes in clinical management, supporting selective rather than routine use. In this narrative review, we synthesize published evidence and expert clinical experience to define the potential role of late-timepoint 68Ga-PSMA-11 PET/CT. We position late-timepoint imaging as a selective, management-focused strategy that can provide complementary information when the standard acquisition leaves a clinically actionable question unresolved. The highest-value applications include early BCR with uncertain local-only versus local-plus-regional nodal recurrence, indeterminate pelvic or metastatic uptake, and suspected local recurrence adjacent to physiologic urinary activity. In appropriately selected cases, a late acquisition may be readily integrated into the established PET workflow using the same imaging system and acquisition framework, enabling patient-specific temporal or postvoid information to refine staging and support individualized treatment planning. We propose a management-anchored framework and practical workflow, based on published literature and clinical experience, to support selective, operationally feasible, and patient-centered use.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-11-19
DOI
https://doi.org/10.3390/cancers18223703
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Selective Late-Timepoint 68Ga-PSMA-11 PET/CT in Prostate Cancer: A Management-Focused Framework

Randy Yeh, Ken Herrmann, Stefano Fanti, Munir V. Ghesani
Cancers
Prostate Cancer Diagnosis and Treatment
article

Selective Late-Timepoint 68Ga-PSMA-11 PET/CT in Prostate Cancer: A Management-Focused Framework

Randy Yeh, Ken Herrmann, Stefano Fanti, Munir V. Ghesani
article en

Abstract

68Ga-PSMA-11 PET/CT has the most established evidence base among PSMA-targeted imaging agents for prostate cancer and is incorporated into clinical guidelines internationally for initial staging, prostate-specific antigen (PSA) persistence, biochemical recurrence (BCR), and selection for PSMA-directed therapy. Its integration into routine clinical practice reflects established acquisition workflows and consistently high diagnostic performance, including localization of small-volume nodal and distant disease that may be occult on conventional imaging. Imaging is generally performed approximately 60 min after 68Ga-PSMA-11 administration; however, interest in additional image acquisition at a later timepoint (i.e., late-timepoint imaging) has emerged, with evidence from published studies and real-world experience from centers of excellence supporting feasibility and utility for select clinical scenarios. This additional late (generally 90 min to 3 h) acquisition may improve lesion-to-background contrast or help characterize low-level uptake, indeterminate findings, and suspected recurrence adjacent to physiologic urinary activity. However, improved contrast or lesion detection does not consistently translate into changes in clinical management, supporting selective rather than routine use. In this narrative review, we synthesize published evidence and expert clinical experience to define the potential role of late-timepoint 68Ga-PSMA-11 PET/CT. We position late-timepoint imaging as a selective, management-focused strategy that can provide complementary information when the standard acquisition leaves a clinically actionable question unresolved. The highest-value applications include early BCR with uncertain local-only versus local-plus-regional nodal recurrence, indeterminate pelvic or metastatic uptake, and suspected local recurrence adjacent to physiologic urinary activity. In appropriately selected cases, a late acquisition may be readily integrated into the established PET workflow using the same imaging system and acquisition framework, enabling patient-specific temporal or postvoid information to refine staging and support individualized treatment planning. We propose a management-anchored framework and practical workflow, based on published literature and clinical experience, to support selective, operationally feasible, and patient-centered use.

CancersVol. 18(22)
Mount Sinai Hospital (US), IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT), Essen University Hospital (DE), Parents' Place of Maryland (US), Deutsches Konsortium für Translationale Krebsforschung (DE), University of Duisburg-Essen (DE)
Prostate Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon